STOCK TITAN

Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Bicycle Therapeutics to participate in fireside chat at Morgan Stanley conference
Positive
  • Participation in Morgan Stanley conference could enhance visibility and investor interest
Negative
  • None.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023, at 10:10 a.m. ET.

A live webcast of the fireside chat will be accessible in the Investors & Media section of Bicycle Therapeutic’s website at www.bicycletherapeutics.com. An archived replay of the webcast will be available following the event.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase 1/2 trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase 1/2a clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA. For more information, visit bicycletherapeutics.com.

Investors:

Stephanie Yao

SVP, Investor Relations & Corporate Communications

ir@bicycletx.com

617-945-8155

Media:

Argot Partners

Sarah Sutton

bicycle@argotpartners.com

212-600-1902

Source: Bicycle Therapeutics

Bicycle Therapeutics plc American Depositary Shares

NASDAQ:BCYC

BCYC Rankings

BCYC Latest News

BCYC Stock Data

1.38B
46.59M
1.3%
92.35%
4.73%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE